about bpl

Bio Products Laboratory Ltd.


FDA Accepts BPL’s Amended BLA Submission for Coagadex® (Coagulation Factor X, Human)

ELSTREE, UK AND DURHAM, NC - May 27, 2015 – Bio Products Laboratory, Ltd. (BPL), a leading manufacturer of plasma-derived therapies, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the company’s amended Biologics License Application for Coagadex® for hereditary ...

Date added: Friday 29th May 2015
Latest updated: Wednesday 8th February 2017

Patient information leaflets